

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kaisa Health Group Holdings Limited
佳兆業健康集團控股有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 876)

**SUPPLEMENTAL ANNOUNCEMENT TO THE ANNUAL REPORT
FOR THE YEAR ENDED 31 DECEMBER 2020**

References are made to the annual report of Kaisa Health Group Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) for the year ended 31 December 2020 (the “**2020 Annual Report**”). Unless otherwise stated, capitalised terms used herein shall have the same meanings as defined in the 2020 Annual Report.

In addition to the information disclosed in the 2020 Annual Report, the board (the “**Board**”) of directors of the Company would like to provide the following supplemental information to note 31 (*Share Options*) to the financial statements of the 2020 Annual Report.

As stated in the 2020 Annual Report, during the year ended 31 December 2020, options were granted on 22 July 2020 and the estimated fair values of the options granted on that date were HK\$12,121,000. Out of the 148,000,000 share options granted on 22 July 2020, 138,000,000 share options were granted to directors and chief executive of the Company and 10,000,000 share options were granted to employees of the Group. The fair value of the options granted in respect of each of the grantees are as follows:

Name of the grantee	Capacity	Number of shares of the Company to be issued upon exercise of the options granted to such grantee in full	Fair value of the options granted (in HK\$'000)
Mr. Zhang Huagang	Executive Director and Chairman of the Board	50,000,000	4,096
Mr. Luo Jun	Executive Director, Co-Vice Chairman of the Board and chief executive officer of the Company	40,000,000	3,276
Mr. Wu Tianyu	Executive Director and Co-Vice Chairman of the Board	20,000,000	1,638
Dr. Liu Yanwen	Independent non-executive Director	6,000,000	491
Mr. Fok Hei Yu	Independent non-executive Director (<i>resigned on 4 March 2021</i>)	6,000,000	491
Dr. Lyu Aiping	Independent non-executive Director	6,000,000	491
Ms. Jiang Sisi	Chief operating officer of the Company and spouse of Mr. Wu Tianyu	10,000,000	819
Employees		10,000,000	819

The closing price of the shares of the Company immediately before the date of grant was HK\$0.142.

The above supplemental information does not affect other information contained in the 2020 Annual Report and the contents of the 2020 Annual Report remain correct and unchanged.

By Order of the Board
Kaisa Health Group Holdings Limited
Zhang Huagang
Chairman

Hong Kong, 25 June 2021

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Zhang Huagang (Chairman), Mr. Luo Jun (Co-Vice Chairman), Mr. Wu Tianyu (Co-Vice Chairman) and Mr. Kwok Ying Shing, and three independent non-executive Directors, namely Dr. Liu Yanwen, Dr. Lyu Aiping and Ms. Li Yonglan.